posted on 2019-01-31, 00:33authored bySylvain Brohee, Amir Sonnenblick, David Venet
This dataset contains data files and identifiers for original data sources for 39 gene expression datasets from over 7,000 individuals with estrogen receptor positive (ER-positive) Breast Cancer (BC).
Background
The related study developed a novel in silico approach to assess activation of different signalling pathways. The phosphatidylinositol 3-kinase (PI3K)/AKT/mTOR signalling pathway mediates key cellular functions, including growth, proliferation and survival and is frequently involved in carcinogenesis, tumor progression and metastases. This research seeks to target relative contribution of AKT and mTOR (downstream of PI3K) in BC outcomes using the in silico approach via integrated reverse phase protein array (RPPA) and matched gene expression.
Methods and sample size
The methodology includes the development of gene signatures that reflect level of expression of pAKT and p-mTOR separately. Pooled analysis of gene expression data from over 7,000 patients with ER-positive BC was then performed. This data record holds links to the repositories holding these data, as well as the R-data files for each data record used in the analysis. All gene signatures developed are captured in Supplementary Data Sonnenblick.pdf.xlsx
Data sources
The dataset name, relevant DOI, accession number or access requirements are listed alongside the file type and repository name or other source where applicable.
GEO=Gene Expression Omnibus
EGA=European Genome-phenome Archive
This data table is available to download as NPJBCANCER-00304R1-data-sources.xlsx including more detailed information and web urls to each data source. data_db.tab contains more detailed technical metadata for each data source.
AS is supported by a Clinical Research Career Development Award from the Israel Cancer Research Fund grants (16-116-CRCDA) and from the Israeli cancer research association (2017-0140). AS was an ESMO translational research fellow. CS is supported by the Breast Research Cancer Foundation (BCRF).